Strive Financial Group’s Bio-Rad Laboratories Class A BIO Stock Holding History

Strive Financial Group’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$4.16K	Buy	+11	New	+$3.84K	﹤0.01%	838

Other funds holding BIO

First Eagle Investment Management New York $63.7B AUM 20.33% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Ariel Investments Chicago, Illinois $9.6B AUM 22.21% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $25.4B AUM 35.48% 1-Year Est. Return

Neuberger Berman Group New York $148B AUM 31.56% 1-Year Est. Return

Strive Financial Group's BIO Position: Q3 2026 in Review

Strive Financial Group opened a new position in Bio-Rad Laboratories Class A (BIO) in Q3 2026: 11 shares worth $4.16K. The stake represents ﹤0.01% of the portfolio and ranks #838 among its holdings.

327 funds tracked by Wall St. Rank hold BIO as of Q3 2026.

Strive Financial Group held 11 shares of Bio-Rad Laboratories Class A worth $4.16K as of Q3 2026.
Bio-Rad Laboratories Class A was a new Strive Financial Group position in Q3 2026.
Bio-Rad Laboratories Class A made up ﹤0.01% of Strive Financial Group's portfolio in Q3 2026, its #838 holding.
327 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2026.

Based on Strive Financial Group's 13F filing for Q3 2026, filed 9 Nov 2026.